Compare KRNY & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KRNY | FDMT |
|---|---|---|
| Founded | 1884 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 511.9M | 479.9M |
| IPO Year | 2014 | 2019 |
| Metric | KRNY | FDMT |
|---|---|---|
| Price | $8.06 | $8.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $8.50 | ★ $31.71 |
| AVG Volume (30 Days) | 257.6K | ★ 652.3K |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | ★ 5.33% | N/A |
| EPS Growth | ★ 130.22 | 18.79 |
| EPS | ★ 0.30 | N/A |
| Revenue | $2,580,000.00 | ★ $85,209,000.00 |
| Revenue This Year | $3.89 | N/A |
| Revenue Next Year | $17.52 | $70.28 |
| P/E Ratio | $27.50 | ★ N/A |
| Revenue Growth | 36.00 | ★ 230194.60 |
| 52 Week Low | $5.76 | $3.03 |
| 52 Week High | $8.50 | $12.34 |
| Indicator | KRNY | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 55.49 | 40.43 |
| Support Level | $7.77 | $8.25 |
| Resistance Level | $8.27 | $10.70 |
| Average True Range (ATR) | 0.22 | 0.49 |
| MACD | 0.01 | -0.14 |
| Stochastic Oscillator | 74.52 | 4.95 |
Kearny Financial Corp is a federally-chartered stock savings bank. The bank is engaged in the business of attracting deposits from the general public in New Jersey and New York, and using these deposits, together with other funds, to originate or purchase loans for its portfolios and invest in securities. The bank's loan portfolio is chiefly comprised of loans collateralized by commercial and residential real estate. The bank's primary source of income is net interest income.
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).